438475-37-7

Usage

Uses

Used in Pharmaceutical Research:
CHEMBRDG-BB 4013290 is used as a chemical compound in pharmaceutical research for its potential biological activity. Its unique structure as a thiazole derivative containing fluorine and sodium may contribute to its potential applications in drug discovery and development.
Used in Drug Discovery and Development:
CHEMBRDG-BB 4013290 is used as a synthetic compound in drug discovery and development. Its specific properties and potential biological activity make it a candidate for further research and exploration in the pharmaceutical industry. However, more information on its pharmacological and toxicological properties is needed to fully understand its potential applications and safety.

InChI:InChI=1/C5H7ClN2/c6-2-1-5-3-7-8-4-5/h3-4H,1-2H2,(H,7,8)

Upstream product

• 177940-20-4 3-(diethoxymethyl)-2-ethoxytetrahydrofuran 
• 180207-57-2 2-(1H-pyrazol-4-yl)ethan-1-ol 

Downstream Products

• 796845-58-4 2-(1-methyl-1H-pyrazol-4-yl)ethanamine 
• 1195687-62-7 N-[2-(1H-pyrazol-4-yl)-ethyl]-phthalimide 

Relevant academic research and scientific papers

Water-soluble derivatives of octanuclear iron-oxido-pyrazolato complexes - An experimental and computational study

Two water-soluble iron-pyrazolato complexes (compounds 3 and 4), [Fe 8], have been prepared by introducing twelve hydroxyalkyl groups to the periphery of the approximately spherical octanuclear molecule. They are contrasted with their two organosoluble chloroalkyl analogues (compounds 1 and 2). All four complexes were characterized in solution by 1H NMR and electrospray ionization mass spectrometry. The one-electron-reduction product of water-soluble 3, [Fe8]-, was structurally characterized by single-crystal X-ray diffraction analysis. In aqueous media, the four terminal Fe-Cl bonds of [Fe8] are partially hydrolyzed, and the resulting chlorido-aqua-hydroxido species form supramolecular nanoscale aggregates, as determined by dynamic light scattering and electron microscopy. Preliminary computational studies with DFT methods were employed to model the H-bonding interactions controlling the competing solvation and aggregation processes. Twelve hydroxyalkyl pendant groups render an octanuclear iron-oxido-pyrazolato complex soluble in water, where partial hydrolysis and extended intermolecular H-bonding interactions result in supramolecular assemblies. Copyright

1,2,5-oxadiazole derivative used as indoleamine 2,3-dioxygenase inhibitor

The invention belongs to the technical field of 1,2,5-oxadiazole derivatives, and particularly relates to a 1,2,5-oxadiazole derivative or a pharmaceutically acceptable salt thereof which is used as an indoleamine 2,3-dioxygenase inhibitor. The structure of the 1,2,5-oxadiazole derivative or the pharmaceutically acceptable salt thereof used as the IDO inhibitor is shown in the following formula I.The invention provides a general formula compound I with a novel structure. Experimental results show that some compounds have excellent IDO inhibitory activity and permeation performance at the sametime. The compound is expected to be marketed as a tumor molecular immunotherapeutic drug for cancer treatment.

HETEROARYL-CARBOXAMIDES AS HISTONE DEMETHYLASE INHIBITORS

The invention relates to heteroaryl-carboxamides as described herein, useful as histone demethyiase inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy, including e.g., in the treatment of cancer.

HETEROARYL-CARBOXYLIC ACIDS AS HISTONE DEMETHYLASE INHIBITORS

The invention relates to heteroaryl-carboxylic acids as described herein, useful as histone demethylase inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy, including e.g., in the treatment of cancer.